logo
logo
Sign in

Migraine Drugs Market Revenue Growth, New Launches, Regional Share Analysis & Forecast Till 2026

avatar
jhon tanison

 

Rising prevalence of migraine, intense pipeline activity, enhanced use of novel drug classes, rising consumption of unhealthy food, and high-pressure lifestyle are key factors contributing to a high CAGR of migraine drugs market during the forecast period.

Market Size – USD 1.29 Billion in 2018, Market Growth - CAGR of 13.3%, Market Trends– Launch of calcitonin gene-related peptide therapies and increasing acceptance of novel drugs

According to the current analysis of Reports and Data, the global Migraine Drugs market was valued at USD 1.29 billion in 2018 and is expected to reach USD 3.51 billion by the year 2026, at a CAGR of 13.3%. Migraine treatments are intended to stop the symptoms or for preventing future attacks on the patients. The factors driving the growth of the target market include the increasing awareness about novel drug classes and the rising incidence of migraines problems across the globe. Also, the launch of calcitonin gene-related peptide (CGRP) is expected to drive the growth of this industry. Migraine is defined as a type of intense and recurring headache accompanied by phonophobia, photophobia, and nausea. The condition arises due to genetic origins. However, emotional imbalances such as depression, stress, anxiety, shock, and excitement can trigger migraine attacks.

There have been various types of medication alternatives for preventing and healing migraines but has severe side effects as well, ranging from weight changes, dizziness, nausea and more in an adult with no background of any other medical condition. For women in pregnancy, sumatriptan are the safest option for the treatment and anticonvulsant medicines are contraindicated. However, the approval of the U.S. Food and Drug Administration for the new class of drug specially designed to treat migraine has transformed the market positively. The new FDA approved drugs are Aimovig (Erenumab), Emgality and Ajovy. In September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for Emgality (galcanezumab-gnlm), a 120 mg injection for the preventive treatment of migraine in adults.

 Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2515

The report puts an emphasis on the information regarding the key players with a special focus on their company profile, business overview, recent advancements, product catalog, and strategic business plans. It provides a comprehensive overview of the strategic alliances in the market under taken by the key players such as mergers and acquisitions, joint ventures, collaborations, partnerships, agreements, product launches, brand promotions, and corporate deals, among others.

Key companies operating in the market and profiled in the report include:

Pfizer, GlaxoSmithKline, Allergan, Amgen, Eli Lilly, Teva Pharma, Biohaven Pharma, Abbott Laboratories, Johnson & Johnson, and Valeant Pharma

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2515

The Migraine Drugs market takes into account major geographical locations such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa to offer key insights into market growth, market size, market share, revenue growth, current and emerging trends, supply and demand ratio, import/export, consumer demand and behavior, and presence of key players in each region. The report offers an in-depth country wise analysis to impart better understanding of the market and its growth prospects.

Segments Covered in the report

Product Outlook (Revenue in Million USD; 2016–2026)

  • Pain Relieving Medication
    • Pain Reliever
      • Aspirin
      • Ibuprofen
    • Triptans
      • Rizatriptan
      • Sumatriptan 
    • Ergot Alkaloid
      • Dihydroergotamines
      • Ergotamine
      • Lasmiditan
    • Opioid Medication
      • OxyContin
      • Vicodin
      • Percocet
      • Others
    • Anti-Nausea Drugs
      • Chlorpromazine
      • Metoclopramide
      • Prochlorperazine
    • Preventive Medications
      • Blood Pressure Lowering Medications
        • Beta blockers
        • Calcium channel blockers

Route of Administration Outlook (Revenue in Million USD; 2016–2026)

  • Oral
  • Injectable
  • Nasal Sprays
  • Others

Distribution Channel Outlook (Revenue in Million USD; 2016–2026)

  • Hospitals Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Key Regions Analyzed in the Report include:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Rest of MEA

To know more about the report @ https://www.reportsanddata.com/report-detail/migraine-drugs-market

Furthermore, it consists information about individual segment of the Migraine Drugs market based on the types and application. The report also offers insights about the key segments expected to register significant revenue growth over the forecast period and primary trends influencing their growth. It also offers CAGR and market share values for each segment to provide clear understanding of demand and trend in the global market.

Key Benefits of the Report:

  • Comprehensive overview of the changing dynamics of competitive landscape
  • Detail oriented futuristic prospects of factors driving and restraining growth of the market
  • Valuable insights on key market growth driving trends and monetary competence in the forecast period
  • Strategic recommendations to key players and new entrants to overcome barriers and challenges in the market
  • Revenue forecasts for the period of 2021-2027

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2515

Thank you for reading our report. For any specific details on customization of this report, please get in touch with us. We will ensure the report you get is well-suited to your needs.

 Browse More Reports:

Gonorrhea Testing Market

Joint Replacement Market

 

 

 

collect
0
avatar
jhon tanison
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more